Free Trial

Lixte Biotechnology (LIXT) Competitors

$2.53
+0.18 (+7.66%)
(As of 07/18/2024 ET)

LIXT vs. SNGX, PPBT, TXMD, VIRX, KALA, IBIO, BFRG, VINC, NNVC, and CPIX

Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Soligenix (SNGX), Purple Biotech (PPBT), TherapeuticsMD (TXMD), Viracta Therapeutics (VIRX), KALA BIO (KALA), iBio (IBIO), Bullfrog AI (BFRG), Vincerx Pharma (VINC), NanoViricides (NNVC), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceutical preparations" industry.

Lixte Biotechnology vs.

Lixte Biotechnology (NASDAQ:LIXT) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, community ranking, media sentiment, profitability, dividends, risk and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lixte Biotechnology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Soligenix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Lixte Biotechnology has a beta of -0.21, meaning that its share price is 121% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500.

Lixte Biotechnology has a net margin of 0.00% compared to Soligenix's net margin of -1,025.66%. Soligenix's return on equity of -198.36% beat Lixte Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Lixte BiotechnologyN/A -2,545.46% -115.60%
Soligenix -1,025.66%-198.36%-61.43%

5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 15.5% of Lixte Biotechnology shares are held by company insiders. Comparatively, 1.4% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Soligenix received 278 more outperform votes than Lixte Biotechnology when rated by MarketBeat users.

CompanyUnderperformOutperform
Lixte BiotechnologyN/AN/A
SoligenixOutperform Votes
278
72.97%
Underperform Votes
103
27.03%

Lixte Biotechnology has higher earnings, but lower revenue than Soligenix. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lixte BiotechnologyN/AN/A-$5.09M-$2.33-1.09
Soligenix$840K7.53-$6.14M-$11.52-0.55

In the previous week, Lixte Biotechnology had 1 more articles in the media than Soligenix. MarketBeat recorded 2 mentions for Lixte Biotechnology and 1 mentions for Soligenix. Lixte Biotechnology's average media sentiment score of 0.96 beat Soligenix's score of 0.83 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lixte Biotechnology
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Soligenix
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Lixte Biotechnology beats Soligenix on 7 of the 13 factors compared between the two stocks.

Get Lixte Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LIXT vs. The Competition

MetricLixte BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.69M$7.02B$5.21B$8.44B
Dividend YieldN/A2.73%2.82%3.97%
P/E Ratio-1.0920.38155.4918.33
Price / SalesN/A279.682,068.5578.34
Price / CashN/A34.4936.4134.84
Price / Book11.505.794.904.50
Net Income-$5.09M$147.01M$110.92M$216.05M
7 Day Performance6.75%-0.16%0.97%1.78%
1 Month Performance2.43%6.89%7.41%6.05%
1 Year Performance-50.97%-4.32%4.39%0.89%

Lixte Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNGX
Soligenix
0 of 5 stars
0.00 / 5 stars
$7.43
-2.9%
N/A-37.6%$7.55M$-140,149.00-0.6413Gap Down
PPBT
Purple Biotech
1.8676 of 5 stars
1.87 / 5 stars
$0.40
+5.3%
$9.00
+2,154.5%
-69.9%$10.08MN/A-0.4920Gap Up
TXMD
TherapeuticsMD
0 of 5 stars
0.00 / 5 stars
$1.85
+3.9%
N/A-54.2%$21.33M$1.30M0.001Analyst Forecast
Gap Up
VIRX
Viracta Therapeutics
1.9637 of 5 stars
1.96 / 5 stars
$0.54
+8.0%
$6.50
+1,108.2%
-62.4%$21.13MN/A-0.4440Positive News
Gap Down
KALA
KALA BIO
3.9513 of 5 stars
3.95 / 5 stars
$7.48
+3.3%
$16.50
+120.6%
-48.6%$21.09M$3.89M-0.4943Gap Down
IBIO
iBio
0 of 5 stars
0.00 / 5 stars
$2.44
+13.0%
$5.00
+104.9%
N/A$21.03M$2.38M0.0026
BFRG
Bullfrog AI
0.1192 of 5 stars
0.12 / 5 stars
$2.64
+20.0%
N/A-30.2%$20.72M$60,000.00-3.004Short Interest ↑
News Coverage
VINC
Vincerx Pharma
2.2114 of 5 stars
2.21 / 5 stars
$0.69
+4.5%
$5.00
+621.7%
-44.5%$20.56MN/A-0.3942
NNVC
NanoViricides
0 of 5 stars
0.00 / 5 stars
$1.74
-3.3%
N/A+33.7%$20.55MN/A-2.127Analyst Downgrade
CPIX
Cumberland Pharmaceuticals
0 of 5 stars
0.00 / 5 stars
$1.49
+3.5%
N/A-2.6%$20.44M$38.83M-2.5391Positive News

Related Companies and Tools

This page (NASDAQ:LIXT) was last updated on 7/18/2024 by MarketBeat.com Staff

From Our Partners